Published in final edited form as:

Biochim Biophys Acta. 2011 December ; 1816(2): 147–157. doi:10.1016/j.bbcan.2011.05.005.

Ubiquitin-independent proteasomal degradation during oncogenic viral infections

Jiwon Hwang¹, Laura Winkler¹, and Robert F. Kalejta^{*}

Institute for Molecular Virology and McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53706 USA

Abstract

Most eukaryotic proteins destined for imminent destruction are first tagged with a chain of ubiquitin molecules and are subsequently dismantled by the proteasome. Ubiquitin-independent degradation of substrates by the proteasome, however, also occurs. The number of documented proteasome-dependent, ubiquitin-independent degradation events remains relatively small but continues to grow. Proteins involved in oncogenesis and tumor suppression make up the majority of the known cases for this type of protein destruction. Provocatively, viruses with confirmed or suspected oncogenic properties are also prominent participants in the pantheon of ubiquitin-independent proteasomal degradation events. In this review, we identify and describe examples of proteasome-dependent, ubiquitin-independent protein degradation that occur during tumor virus infections, speculate why this type of protein destruction may be preferred during oncogenesis, and argue that this uncommon type of protein turnover represents a prime target for antiviral and anticancer therapeutics.

1. Introduction

Protein turnover is a tightly controlled process that regulates myriad pathways to maintain cellular homeostasis and modulate the cellular environment [1-4]. The majority of protein degradation is accomplished by the proteasome, a large catalytic complex essential for processes such as cell cycle progression, transcription, DNA repair, apoptosis, and angiogenesis, all of which, when aberrant, can influence cellular growth control as it relates to cancer [5-12]. Furthermore, proteasome function is an essential component in the replication of many viruses, as well as in antiviral immune defenses [13-15]. Many of these viruses have been causally linked or casually associated with human cancers [13-14]. While proteasomes most often degrade substrate proteins tagged with polyubiquitin chains [16], they can also degrade non-ubiquitinated proteins [17]. Interestingly, proteasome-dependent, ubiquitin-independent degradation is prominently represented during viral infections linked to cancer, and many substrates of this reaction, in both infected and uninfected cells, are proteins that control cell growth and tumorigenesis. Below, we discuss ubiquitin-independent proteasomal degradation with a specific focus on viral infections and oncogenic transformation.

© 2011 Elsevier B.V. All rights reserved.

^{*}corresponding author (rfkalejta@wisc.edu) 608-265-5546 fax: 608-262-4570 .

¹These authors contributed equally to this work

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

2. Protein proteasomal degradation

2.1. Proteasome components and activators

The catalytic component of the proteasome is a 700 kDa assembly that sediments in sucrose gradients with a buoyant density of 20 Svedberg units and thus is referred to as the 20S core particle (CP) [18]. It is composed of α and β subunits that form a barrel-like structure. Two sets of seven distinct α subunits form two identical rings separated by two (identical and adjacent) rings of seven distinct β subunits (Figure 1). The catalytic surface responsible for the proteolytic processing of substrates is formed by the $\beta 1$, $\beta 2$ and $\beta 5$ subunits and is found within the interior of the channel generated by their ring-like organization [18]. Access to these sites is restricted to proteins that can enter the narrow channel [18-21]. Proteasome activators, such as the 19S regulatory particle (RP), can associate with either or both ends of the 20S CP [22]. The combination of one 20S CP and one or two 19S RPs generates a larger complex referred to as the 26S proteasome that is responsible for the majority of protein degradation that occurs in mammalian cells [22]. The 19S RP consists of six ATPase and twelve non-ATPase subunits that mediate substrate and ubiquitin chain recognition, ATP-dependent substrate unfolding and insertion into the 20S CP, and the release of ubiquitin molecules that were covalently attached to targeted substrates [23].

In addition to the 19S RP, other proteasome activators (PA) can associate with the 20S CP to modulate proteasome function [22]. These include PA200 and three isoforms (α , β and γ) of PA28 (Figure 2). PA28 α and PA28 β form a heteroheptameric complex that may play a role in the processing of antigens for display by major histocompatibility complex (MHC) class I proteins [24]. Along with interferon-inducible β subunits, it forms the immunoproteasome. PA28 γ forms a homoheptamer that has been specifically implicated in the ubiquitin-independent turnover of several substrates [22]. PA200 appears to upregulate the caspase-like activity of the proteasome and may play a role in the cellular DNA damage response [25-26].

2.2. Ubiquitin-mediated proteolysis

The majority of substrates that are destined for degradation by the proteasome are covalently modified with ubiquitin molecules [16]. Ubiquitin is a 76 amino acid protein that can be covalently linked via its C-terminal amino acid to protein substrates at N-terminal or lysine residues. Ubiquitin chains are assembled by the addition of subsequent molecules (again via their C-termini) to one of seven lysine residues found within the ubiquitin molecule bound to the substrate. Often, a chain of at least four ubiquitin molecules, linked through their lysine 48 residue, promotes recognition and proteolysis by the proteasome, although there are documented exceptions to this rule [16, 27]. Prior to substrate attachment or chain growth, ubiquitin monomers must first be activated by one of two E1 ubiquitin activating enzymes, subsequently transferred to one of several E2 ubiquitin conjugating enzymes, and ultimately covalently bound to target proteins with the help of one of the hundreds of E3 ubiquitin ligases. E3s provide the substrate specificity for the ubiquitination reaction [16]. In some circumstances, E4 proteins facilitate chain growth after the addition of the first ubiquitin molecule [28].

The role of polyubiquitin chains in directing covalently marked proteins for proteasomal degradation appears simply to be attaching targeted substrates to the proteasome by direct interaction with the Rpn13 and Rpn10 subunits of the 19S RP [29-31]. A subsequent, perhaps ubiquitin-independent step, requires partial substrate denaturation that promotes a higher affinity proteasomal association and perhaps facilitates delivery into the narrow channel leading to the protease active sites buried deep within the proteasome core [32].

Thus, ubiquitin modification acts to deliver substrates to the proteasome where modifications to their tertiary structure produce substrates amenable to efficient degradation.

2.3. Proteasomal function during oncogenesis

The proteasome mediates the majority of cellular protein turnover and is required for cellular homeostasis. Not surprisingly, deregulated protein degradation by the proteasome is observed in a variety of cancers [12]. Aberrant turnover of tumor suppressors, cell cycle regulators, as well as proapoptotic proteins, can promote tumorigenesis and/or exacerbate malignancy. Because of its important role in the induction and maintenance in tumor development, proteasome inhibition has been suggested as a broadly applicable therapeutic for cancers [12, 33]. Transformed cells can be significantly more sensitive to proteasome inhibition than their untransformed counterparts. Proteasome inhibition not only induces apoptosis in transformed cell lines [34], but also sensitizes tumors to conventional therapeutics [35].

2.4. Proteasomal function during viral infection

Aberrant protein degradation is observed in a variety of cancers, including cancers induced by viral infection. Viruses are obligate intracellular parasites that commandeer proteasome function in order to degrade specific cellular targets to promote viral replication [13-14]. Collateral effects of such events sometimes perturb the cellular environment to an extent that causes disease, such as cancer. For example, the ubiquitin-dependent proteasomal degradation of p53 and the retinoblastoma (Rb) tumor suppressor by the oncogenic human papillomavirus [36] and the degradation of NF- κ B by human T cell leukemia virus type 1 [37] are well-documented examples of tumor induction through viral-mediated degradation of critical cellular growth-control regulators.

Paradoxically, the proteasome is utilized both by viruses to enhance their replication [13-14, 38], and by cells to generate viral peptide antigens that are presented via MHC molecules for immune detection and pathogen elimination [39]. Thus, while inhibiting certain proteasome-mediated proteolytic events may indeed produce antiviral effects, inhibiting others could actually exacerbate viral infections. Therefore, studying uncommon mechanisms employed by viruses to usurp proteasome function in order to promote viral replication may provide insights into ways in which these instances of proteasome function can be specifically inhibited for antiviral effect while preserving the natural antiviral effects of more native proteasomal functions.

2.5. Ubiquitin-independent proteasomal degradation

Although the majority of protein turnover mediated by the proteasome occurs through the canonical ubiquitin-dependent pathway, the number of examples of proteasomal degradation that occur without prior ubiquitination is growing [17]. Garnering acceptance that a protein is degraded in a living cell by a proteasome-dependent, ubiquitin-independent pathway is challenging because of the nature of the assays that examine this phenomenon and because many researchers are skeptical that such pathways exist or are biologically relevant. Common assays used to test for ubiquitin-independent degradation have been previously reviewed [17], and each display unique strengths and weaknesses (Table 1). Unfortunately, many of the assays used to examine ubiquitin-independent degradation are considered successful when a negative result is obtained [17]. For example, the absence of ubiquitin-conjugated intermediates during conditions of substrate destabilization, the failure of dominant-negative ubiquitin to inhibit substrate destruction, the inability to stabilize substrates in cells with conditional alleles of the ubiquitin activating enzyme Ube1 or when all substrate lysine residues are substituted are often used as evidence of a ubiquitin-independent pathway. While biochemical assays might show that non-ubiquitinated proteins

can be degraded by the proteasome *in vitro*, they cannot demonstrate that such an event actually occurs *in vivo*. Therefore, even as examples of ubiquitin-independent degradation accumulate, the general acceptance of this pathway will only be achieved by the demonstration of detailed mechanisms that mediate these unique proteolytic events.

Ubiquitin-independent degradation generally occurs through one of two mechanisms (Figure 1), either substrate association with the 20S CP (often with the assistance of additional proteins), or through the function of proteasome activators (Figure 2), complexes that associate with and modulate the function of the 20S CP. Examples of 20S-mediated ubiquitin-independent degradation (Figure 1) include structurally abnormal, misfolded, aged, or highly oxidized proteins [17]. The exposure of hydrophobic patches in such substrates likely enhances recognition by the 20S CP, and their unfolded nature likely obviates the need for 19S RP function. Such observations have led to the theory that a protein presented to the 20S CP in a partially denatured state would not require ubiquitination for degradation. *In vivo*, such proteasomal presentation may require proteins in addition to the substrate itself. For example, the HDM2 protein increases the association of two critical cell cycle regulators, Rb and p21, with the 20S CP, leading to their ubiquitin-independent degradation [40-41]. It is interesting that an E3 ubiquitin ligase, such as HDM2, normally associated with ubiquitin-dependent degradation plays such a critical role in a ubiquitin-independent pathway as well.

Ubiquitin-independent degradation has also been shown to occur with the help of known proteasome activators (Figure 1 and Figure 2). While the 19S RP clearly participates in ubiquitin-dependent degradation, evidence suggests that it also mediates the ubiquitin-independent degradation of ornithine decarboxylase (ODC), a critical enzyme involved in the synthesis of cellular polyamines [17, 42]. In this pathway, ODC associates with antizyme, a cellular protein that inhibits its function, resulting in a conformational change that exposes a C-terminal instability element within ODC that is recognized by the 19S RP without ubiquitination, leading to the rapid turnover of ODC [43-44]. Several documented cases of ubiquitin-independent degradation are also mediated by the proteasome activator PA28 γ [22], including SRC-3 [45], p21 [46], p14 [47], and the hepatitis C virus core protein [48]. PA28 γ may facilitate the ubiquitin-independent degradation of these substrates by acting as a molecular chaperone that recruits substrates to the 20S CP and/or by opening the α ring in order to permit substrate insertion into the catalytic core [49].

It is interesting to note that in many of the examples cited above, the protein eliminated by ubiquitin-independent degradation plays significant roles in cell cycle progression, cellular growth control, and/or oncogenesis. Perhaps not coincidentally, accumulating evidence (Table 2) suggests that oncogenic viruses often commandeer this pathway, a process that may contribute to the oncogenic potential of these viruses. Viral oncoproteins may mediate the ubiquitin-independent degradation of target substrates several different ways (Figure 1). In the next sections we illuminate viral proteins that mediate ubiquitin-independent degradation, as well as viral proteins that are degraded by the cellular ubiquitin-independent pathway. Demonstrated or postulated mechanisms for these reactions (Table 2) will also be discussed.

3. Ubiquitin-independent proteasomal degradation in viral protein-expressing cells

3.1. Double stranded DNA viruses

Viruses with double stranded DNA genomes provide numerous and classic examples of oncogenic pathogens. These include the small DNA tumor viruses, such as adenovirus [50], simian virus 40 [50], and human papillomavirus [51-52], as well as herpesviruses, including

Epstein-Barr virus [51], and Kaposi's sarcoma-associated herpesvirus [51]. Based on its detection in biopsied tumor samples and the pro-oncogenic functions of many of its proteins, another herpesvirus, human cytomegalovirus, has been described as oncomodulatory [53-54]. Proteasome-dependent, ubiquitin-independent protein degradation events mediated by human papillomavirus and cytomegalovirus proteins are described below.

3.1.1. Human papillomavirus—Human papillomavirus (HPV) is the etiological agent of cervical carcinoma, the second most common cancer in women worldwide, and is linked to the development of anal, perianal, vulvar, penile, and oropharyngeal cancers [52]. HPV encodes oncoproteins (E6 and E7) that bind to and induce the proteasomal degradation of key cellular tumor suppressor proteins [55]. Persistent expression of E6 and E7 allows the virus to replicate in cells that are committed to terminal differentiation, but also deregulates cell cycle checkpoints and is necessary for cellular transformation [55]. E7 degrades Rb [56], leading to the release of E2F transcription factors and subsequent expression of cellular factors that drive cell cycle progression [57-58]. E7 associates with members of a cullin-based E3 ubiquitin ligase complex [59], and it has been shown that Rb degradation upon E7 binding is ubiquitin-dependent [56].

E6 degrades p53 [60], a transcription factor that, in response to genotoxic stress, induces cell cycle arrest, apoptosis, and cellular senescence [61]. p53 is mutated in more than 50% of human cancers, attesting to its importance as a tumor suppressor [62-64]. Its levels are normally kept low in cells by the action of HDM2, a cellular E3 ubiquitin ligase [65]. Cellular stresses, such as unscheduled DNA synthesis induced by the loss of Rb proteins, activate and stabilize p53 [61]. In order to counteract effects of p53 that would be deleterious to viral replication, HPV, through its E6 protein, mediates the proteasomal degradation of p53 through multiple pathways [60, 66-67]. E6 binds to E6-associated protein (E6AP), a cellular E3 ubiquitin ligase that does not target p53 in uninfected cells [66]. However, when bound by E6, E6AP promotes the polyubiquitination and proteasomal degradation of p53. E6 binds to two distinct regions within p53, a central DNA-binding domain and the C-terminus [68]. Interaction between E6 and the DNA-binding domain of p53 requires E6AP and promotes the ubiquitination and degradation of p53 [66, 68].

Newer evidence indicates that p53 can also be degraded in a ubiquitin-independent manner in the presence of E6, and provides a rationale for the viral protein interacting with the C-terminus of the tumor suppressor [67]. A dominant-negative form of ubiquitin (7KR) in which all seven lysines are substituted with arginines was able to fully inhibit HDM2-mediated destruction of p53, but not E6-mediated p53 degradation. Identical results were obtained with a different type of dominant-negative ubiquitin (tUb) that represents a string of tandem, uncleavable ubiquitin molecules unable to be conjugated to substrate proteins because of an amino acid substitution (glycine to valine) at the conjugation site. Furthermore, overexpression of E6 resulted in destabilization of exogenous p53 in ts20 cells at the restrictive temperature where a temperature-sensitive E1 ubiquitin activating enzyme is nonfunctional, but was fully stabilized at the restrictive temperature when Mdm2 (the mouse homolog of Hdm2) was co-expressed. Interestingly, while neither of the dominant-negative ubiquitin molecules (7KR or tUb) were able to completely stabilize wild-type p53 in the presence of E6, both succeeded in completely stabilizing a C-terminal deletion mutant [67].

Taken together, these data strongly implicate a ubiquitin-independent mechanism of p53 degradation in the presence of E6 that co-exists with the ubiquitin-dependent degradation also induced by this viral protein. Furthermore, evidence suggests that the association of E6 with the C-terminus of p53 is critical for ubiquitin-independent degradation [67], providing a rationale for this site-specific interaction. If binding of E6 to the C-terminus of p53 were to

expose an unstructured domain to the proteasome, then E6-mediated ubiquitin-independent degradation of p53 may occur through a mechanism similar to antizyme-induced ubiquitin-independent degradation of ODC. Importantly, the relevance of ubiquitin-independent, as opposed to the ubiquitin-dependent degradation of p53 during HPV infection and oncogenesis needs to be further explored.

3.1.2. Cytomegalovirus—Human cytomegalovirus (HCMV) is a ubiquitous betaherpesvirus that promotes significant disease in immunocompromised, immunosuppressed, and immunonaiive individuals [69-70]. HCMV infection is the leading viral cause of birth defects, contributes to graft loss in transplant recipients, and leads to retinitis and blindness in acquired immunodeficiency syndrome (AIDS) patients. HCMV is also associated with certain tumors, including malignant glioma, prostate, colorectal [53], and recently breast cancer [71]. While a causative role has not been demonstrated, the presence of HCMV DNA, mRNA, and proteins in tumors, but not the surrounding healthy tissue, suggests that HCMV either modulates cellular environments to perpetuate malignancy, or preferentially infects tumor cells because they may better support viral replication. HCMV infection (Table 3) induces all of the hallmarks of cancer [72-89]. Interestingly, one of the characteristics of a cancer cell, growth in the absence of mitogenic signals, is a property induced by an HCMV protein through an ubiquitin-independent, proteasome-dependent protein degradation event.

The product of the HCMV UL82 gene, a protein called pp71, is incorporated into the tegument layer of virions [90]. Thus, it is delivered to cells immediately upon viral entry where it interacts with cellular transcriptional co-repressors such as Daxx [91-92], BclAF1 [93], and the tumor suppressors of the retinoblastoma family, Rb, p107, and p130 [94], and induces their proteasomal degradation [93-95]. The degradation of Daxx [95] and BclAF1 [93] stimulates the viral immediate-early gene expression that is essential for the initiation of a productive lytic infection [70]. Not surprisingly, viruses that express pp71 mutants unable to bind [91-92] and degrade [95] Daxx have severe growth defects. pp71 also induces Rb degradation at the start of HCMV infection [96]. Interestingly, this degradation event is not required for viral replication *in vitro* [92], perhaps because HCMV also phosphorylates and inactivates Rb [96]. These multiple, possibly redundant mechanisms may make any single one dispensable [76]. Interestingly, both the degradation of Rb by HCMV pp71 and the phosphorylation of Rb by HCMV UL97 stimulate cell cycle progression [94, 96]. These events may be among the many ways through which HCMV might promote oncogenesis.

When the role of ubiquitin has been examined, pp71-mediated degradation events were found to be ubiquitin-independent [97-98]. Daxx degradation by either ectopically expressed or virion tegument-delivered pp71 continued in ts20 cells at the restrictive temperature, but was inhibited by the proteasome inhibitor lactacytin under these same conditions [98]. This indicates that during HCMV infection, pp71-mediated Daxx degradation is proteasome dependent, but ubiquitin-independent. Experiments in ts20 cells with ectopically expressed proteins came to a similar conclusion for the Rb family proteins [97]. Furthermore, polyubiquitinated p130 intermediates were not detected under conditions where pp71-mediated p130 degradation was observed, and a dominant-negative ubiquitin in which lysine 48 is replaced with arginine (K48R) failed to inhibit pp71-induced p130 degradation. Notably, polyubiquitination and K48R inhibition was observed in the absence of pp71 [97], where p130 is known to be degraded by a ubiquitin-dependent mechanism [99]. The diversity of assays employed engenders confidence that pp71 mediates protein degradation without the need for prior ubiquitination.

The mechanism through which pp71 induces the ubiquitin-independent degradation of its substrates remains an enigma. Modification of substrates with ubiquitin-like molecules has

been shown to target them for degradation [100]. While pp71 does induce the SUMOylation of Daxx, this ubiquitin-like modification does not appear to mediate Daxx degradation by pp71 [101]. Intriguingly, recent evidence indicates that, similar to the case of antizyme-mediated degradation of ODC [102], pp71-mediated degradation of Daxx requires the 19S RP but not other proteasome activators (Winkler and Kalejta, manuscript in preparation). Much more work will be required to clearly define a mechanism for the ubiquitin-independent degradation events catalyzed by this interesting and important viral tegument protein.

In addition to cellular substrates degraded in a proteasome-dependent, ubiquitin-independent manner during HCMV infection, the turnover of a viral protein also occurs in this way. Encoded by the viral UL21 gene, pUL21a is a lysine-less protein with a very short half-life that is stabilized in the presence of the proteasome inhibitor MG132, but not the calpain inhibitor ALLM [103]. Ubiquitinated conjugates of pUL21a have not been detected, and it is not stabilized in ts20 cells at the restrictive temperature. Thus all evidence points to ubiquitin-independent proteasomal degradation [103]. A mechanism for this degradation has not been defined, but the high proline content of the C-terminal domain may represent an unstructured region that, similar to some cellular proteins [104], may participate in its rapid degradation without ubiquitination. Interestingly, even though it is an unstable protein, it is required for efficient viral replication [103]. It will be interesting to determine how pUL21a supports HCMV replication, and if the unusual pathway to its degradation plays any role in that function.

Finally, a murine cytomegalovirus (MCMV) protein is also degraded by a proteasome-dependent, ubiquitin-independent mechanism during infection [105]. Because HCMV replication is restricted to human cells [70], MCMV is often used as an *in vivo* surrogate model [106]. The MCMV pM141 protein is rapidly turned over in the absence of pM140 [107]. It is stabilized by proteasome inhibitors but not in ts20 cells at the restrictive temperature, and ubiquitinated conjugates have not been observed [105]. Hence this appears to be another solid case of ubiquitin-independent degradation. pM141 contains a PEST sequence (a string of amino acids enriched in prolines (P), glutamates (E), serines (S) and threonines (T)) that in other proteins has been implicated in their rapid destruction [108]. Interestingly, binding to pM141 is not sufficient for stabilization [105], but an additional, highly acidic pM140 region of unknown function is also required [105].

3.2. Single stranded DNA viruses

Parvoviruses are small, non-enveloped viruses with single stranded DNA genomes that cause disease in animals by affecting the gastrointestinal tract and lymphatic system, leading to vomiting, diarrhea and immunosuppression [109]. The most identifiable member is adeno-associated virus (AAV), which is employed as a gene therapy vector and in vaccines because of its safety and the availability of simple molecular engineering techniques [110]. Although these viruses are not implicated in oncogenesis, a ubiquitin-independent, proteasome-dependent degradation event occurring in cells infected with minute virus of mice (MVM) is briefly described below.

3.2.1. Minute virus of mice—NS2, one of the two viral non-structural proteins of MVM, is a short-lived protein degraded in a proteasome-dependent, ubiquitin-independent manner [111]. It is stabilized by the proteasome inhibitors lactacystin, epoxomicin, or MG132, but not by dominant-negative ubiquitin or in ts20 cells at the restrictive temperature. In cell culture assays where ubiquitination of cyclin E was observed and where NS2 was rapidly degraded, no ubiquitinated conjugates of the viral protein were detected [111]. Thus the evidence for ubiquitin-independent degradation is strong. While the C-terminus of NS2 is

required to mediate its proteasomal degradation [111], the mechanism through which it does so is unclear. NS2-null mutant viruses show defects in capsid assembly and viral replication in certain cell types [112-113], making a further study of the ubiquitin-independent, proteasome-dependent turnover of this protein desirable.

3.3. Reverse transcribing viruses

Some viruses package RNA genomes into their capsids, but during the replication cycle convert that nucleic acid into DNA through a process called reverse transcription, and thus are referred to as reverse transcribing viruses. Examples associated with human tumors include the hepatitis B virus and retroviruses, such as the human immunodeficiency virus type-1 and human T cell leukemia virus type 1. Proteins expressed by each of these viruses induce proteasome-dependent, ubiquitin-independent degradation events that are described below.

3.3.1. Hepatitis B virus—Infection of hepatitis B virus (HBV) causes liver inflammation, jaundice, both acute and chronic hepatitis, and is strongly associated with hepatocellular carcinoma (HCC) [114]. With more than 350 million chronically infected, persistent infection with HBV is a major health problem worldwide. HBV X protein (HBX) is a multifunctional protein essential for both viral replication and the development of HCC [115-116] that acts as a transcription factor and interferes with nucleotide excision repair [116]. Transgenic mice that express HBX develop liver cancer [117]. Thus HBX appears to be relevant target for an HBV-induced HCC therapy.

HBX is an unstable protein that is polyubiquitinated and subsequently degraded by the proteasome [118]. The responsible E3 ubiquitin ligase has not been identified. HBX is also degraded through a ubiquitin-independent process. A lysine-less mutant of HBX that is not detectably ubiquitinated is still subject to proteasomal degradation with an efficiency that mirrors the wild-type protein [119]. Interestingly, HBX interacts with the Rpt2 component of the 19S RP and multiple subunits of the 20S CP, including $\alpha 4$, $\alpha 7$ and $\alpha 8$ [120-122]. While this association may serve to curtail the turnover of several cellular substrates [120-121], it may also facilitate the proteasomal degradation (ubiquitin-dependent and/or ubiquitin-independent) of HBX itself. Examination of a role for proteasome binding in HBX degradation as well as the use of additional diagnostic assays would solidify the conclusion of ubiquitin-independent degradation.

In addition to proteasome binding, cellular protein chaperones may play a role in HBX degradation. Chaperones are responsible for unfolding substrates to facilitate translocation into the proteasome core particle [123], similar to a postulated role for the 19S RP [124]. Thus chaperone-induced protein unfolding may bypass the need for ubiquitination during proteasomal degradation. Overexpression of human DnaJ homologue-1 (Hdj-1)/Hsp40, a protein chaperone, induces HBX proteasomal degradation [125], as well as the degradation of other, often misfolded proteins [126]. While the ubiquitin-dependence of Hdj-1/Hsp40-induced degradation events has not been examined, it is tempting to speculate that along with direct proteasome binding, chaperone-mediated unfolding may play a part in the proteasome-dependent, ubiquitin-independent degradation of the HBX protein.

3.3.2. Human immunodeficiency virus—HIV infection often leads to the development of AIDS, a disabling, life-threatening illness. From its discovery in 1982, millions have died from AIDS, and more than 30 million people worldwide are living with HIV infection [127]. AIDS patients have a high risk of developing certain cancers, such as Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer [128]. The connection between HIV/AIDS and

cancers is not completely understood, but the link likely depends on a weakened immune system caused by viral infection of CD4⁺ helper T cells [129].

Transcriptional elongation of HIV genes from the integrated pro-virus is dependent upon the viral Tat protein [127, 130]. Tat recruits the cellular PTEF-b kinase complex to phosphorylate the C-terminus of RNA Polymerase II that stalls (at the TAR element) shortly after initiation, thus allowing it to complete transcription of the entire viral genome. As combination therapy with multiple drugs targeting different HIV proteins has proven to be very effective at delaying the onset of AIDS [131], Tat has garnered interest as a novel drug target to complement more conventional antiviral therapies, such as reverse transcriptase and protease inhibitors. Tat is polyubiquitinated on lysine 71 by HDM2, a cellular E3 ubiquitin ligase [132]. However, the ubiquitin chain is linked through lysine 63, not the lysine 48 that normally leads to proteasomal degradation [132]. Thus, ubiquitinated Tat is not destabilized, and is in fact a more potent transcriptional activator than the unmodified protein.

While HDM2 does not direct its degradation, another cellular protein, the p14^{ARF} tumor suppressor, appears to destabilize Tat [133]. In ARF-null cells, Tat is stable, but ARF expression reduces the half-life of Tat in a proteasome-dependent manner. The ubiquitin-dependence of this degradation event has not been fully explored. Substitution of lysine 71 with arginine did not inhibit the ARF-mediated destabilization of a Tat-ubiquitin fusion protein [133], but this is clearly neither a direct nor sufficient test of ubiquitin-independence. ARF physically interacts with PA28 γ , and is itself degraded in a ubiquitin-independent manner [47]. As mentioned above, PA28 γ facilitates the proteasome-dependent, ubiquitin-independent degradation of multiple cellular and viral proteins [134]. Thus ARF might recruit Tat to the PA28 γ complex to induce its ubiquitin-independent proteasomal degradation. Alternatively, direct recognition by other proteasome subunits may (also or instead) be utilized as degradation mechanism(s) because Tat interacts with α and β subunits of the 20S CP [135], as well as the TBP-1 (Tat-binding protein-1) subunit of the 19S RP [136].

3.3.3. Human T cell leukemia virus—Human T cell leukemia virus type 1 (HTLV-1) infection causes adult T cell leukemia (ATL) and the inflammatory neurological disorder HTLV-1-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) [137]. Viral infection of CD4⁺ T cells stimulates their clonal expansion, most likely through the action of the viral regulatory protein Tax [138]. A strong transcriptional transactivator required for efficient viral gene expression [139], Tax immortalizes human primary T lymphocytes [140-141] and can cooperate with Ras to transform primary rat fibroblasts [142]. The oncogenic potential of Tax is largely attributed to its ability to constitutively activate NF- κ B, an event that may be critical for the transformation and survival of cells infected with HTLV-1 [37, 143].

Transcription factors within the NF- κ B family regulate cell growth, differentiation, and survival by binding to the promoters of specific cellular genes and activating their transcription [144]. They themselves are held in check by the I κ B family of inhibitory proteins that interact with NF- κ B members in the cytoplasm and prohibit their translocation to the nucleus [145]. Latent NF- κ B bound to I κ B can be activated in at least two ways, the canonical pathway (where I κ B is phosphorylated, then polyubiquitinated, and subsequently degraded by the 26S proteasome) and the non-canonical pathway (where specific I κ B family members are phosphorylated, then polyubiquitinated and subsequently proteolytically processed by the proteasome into active transcription factors).

It is well established that Tax activates NF- κ B through the canonical pathway by inducing the phosphorylation, ubiquitination, and degradation of I κ B α [143, 146-147]. Mutations at phospho-acceptor residues required for targeting I κ B α to the proteasome are resistant to Tax-mediated degradation in transient transfection assays [146], and mutants with arginine substitutions at the lysine residues that when ubiquitinated lead to I κ B α degradation, act as dominant-negative inhibitors that prevent Tax-mediated induction of NF- κ B activity [147].

Recent evidence implicates Tax in ubiquitin-independent proteolytic events involving the proteasome. Tax was found to act as a molecular bridge between I κ B α and the β 4 subunit of the 20S CP [148]. Furthermore, assays with potentially higher sensitivity than those previously conducted [146-147] detected Tax-mediated degradation of phosphorylation- and ubiquitination-resistant mutants of I κ B α [148]. However, proteasome subunit association and the degradation of these resistant I κ B α mutants have yet to functionally linked. Tax has also been observed to associate with the 20S CP α 3 subunit and the p105 subunit of I κ B, leading to p105 proteasomal processing [149]. Once again, a definitive link between proteasome subunit binding and I κ B processing has not been established. However, it seems possible that Tax may invoke ubiquitin-independent mechanisms to target I κ B to proteasomes for activation of both the canonical and non-canonical NF- κ B pathways. Finally, Tax is also implicated in the degradation of Rb through promoting its association with the 20S CP [150]. Clearly more experimentation is required to specifically demonstrate the ubiquitin-independence of these interesting events, and to elaborate their detailed molecular mechanisms.

3.4. Positive strand RNA viruses

Viruses with single stranded RNA genomes of the same polarity that are translated into proteins are called positive strand RNA viruses. Examples include the rhinoviruses that in part are responsible for common colds [151], polioviruses that cause paralysis but are nearing eradication due to vaccination efforts [152], and the hepatitis C virus that, similar to HBV (see above), causes liver disease and liver cancer [153]. At least two HCV proteins are targeted for proteasome-dependent, ubiquitin-independent degradation through processes described below.

3.4.1. Hepatitis C virus—Worldwide, over 300 million people are infected with hepatitis C virus (HCV), which can lead to hepatic steatosis, cirrhosis, and HCC. The genome of HCV encodes a single polyprotein that is cleaved by host and viral proteases to generate approximately ten distinct viral proteins [153]. One of these, the HCV core protein, modulates cellular processes such as transcription, cell cycle progression, apoptosis, and immune responses, and is implicated in viral pathogenesis, including the development of HCC [154].

HCV core protein is degraded by the proteasome after polyubiquitination at N-terminal lysine residues by E6AP [155]. Because knock-down of E6AP increases virus production, the E6AP-mediated degradation of the core protein appears to be a cellular antiviral defense mechanism [155]. Similar to other proteins discussed above, HCV core also appears to undergo ubiquitin-independent degradation via the proteasome. A lysine-less mutant is not detectably ubiquitinated yet is still relatively unstable and its half-life increased upon proteasome inhibition [156]. HCV core associates with the PA28 γ [48, 157], and expression of PA28 γ accelerated the turnover of both the wild-type and lysine-less mutant proteins that were stabilized in the presence of the proteasome inhibitor MG132 [156]. Importantly, E6AP expression enhanced the degradation of wild-type core, but not the lysine-less mutant. Conversely, knockdown of PA28 γ but not E6AP stabilized the lysine-less mutant, while knockdown of either stabilized wild-type core [156]. These results strongly implicate PA28 γ

in the ubiquitin-independent proteasomal degradation of the HCV core protein. The significance of this event for viral infection or HCV pathogenesis remains to be explored.

The HCV F protein also appears to be degraded in a proteasome-dependent, ubiquitin-independent manner [158]. HCV F is a short-lived protein of unknown function that interacts in various assays with the $\alpha 3$ subunit of the 20S CP [158]. This particular subunit has a flexible N-terminal extension that regulates substrate access to the central catalytic chamber of the 20S CP [159]. Sequences upstream (aa 20–40) and including the $\alpha 3$ binding domain from the F protein (aa 40–60) are sufficient to cause protein destabilization when fused to GFP [158]. This implies that the degradation of this fusion protein (and by extension, wild-type F) may be facilitated simply by the physical interaction between F protein and the $\alpha 3$ subunit of the 20S CP without the need for polyubiquitination. Perhaps this association induces a conformational change in $\alpha 3$ that permits the delivery of F to the proteolytic active sites buried deep within the proteasome core. Indeed, the domain fused to GFP in these experiments lacked lysine residues, and a lysine-less derivative of F is no more stable than the wild-type protein [158]. HCV F was also not stabilized in ts20 cells cultured at the restrictive temperature, but was degraded by purified 20S CP *in vitro* in the absence of ubiquitination machinery. Thus it appears likely that HCV F is degraded in a proteasome-dependent, ubiquitin-independent manner. Similar to the viral core protein, the role that this might play during viral infection of HCC development has not been explored.

4. Conclusions

Most proteins degraded by proteasome-dependent, ubiquitin-independent pathways are involved in growth control processes that, when disrupted, can promote oncogenesis. This is true for both uninfected and virus-infected cells and tumors. One questions whether this seeming over-representation is pathologically relevant or simply a result of the prevalence of cancer research programs and the intense focus on understanding tumor cell biology and the roles of viruses in cancer etiologies.

That caveat aside, here we speculate on why ubiquitin-independent degradation appears to be a prominent component of cancer cell biology. A first point to ponder is why select tumor suppressor proteins are degraded by both ubiquitin-dependent and ubiquitin-independent pathways. Ubiquitin-independent degradation does not require the enzymatic cascade of ubiquitin-conjugation and thus may be faster and more efficient than ubiquitin-dependent degradation. Accelerated and economical protein degradation may be important during embryonic or stem cell cycles and become cryptically activated in virus-infected or tumor cells. Independent mechanisms may also provide a back-up or fail-safe plan to increase the probability that required proliferative events would be realized.

One next must consider why these ubiquitin-independent events are observed more prominently in cancer cells than in normal cell cycles. With fewer mechanistic steps and an apparent lesser potential for regulation, this pathway for protein destruction may be more susceptible to activation through mutation than the multi-component, tightly regulated ubiquitin-dependent process. In addition, cancer cell energetics may favor a more energy-efficient method for at least a subset of the protein destruction that drives cell division. A related point is the significant association of ubiquitin-independent degradation events associated with viral infections. As virus-infected cells and transformed cells can be energetically and metabolically similar, perhaps the same characteristics that may promote association with cancer (ease with which regulatory mechanisms can be bypassed; resource conserving (e.g. ubiquitin pools)) also make ubiquitin-independent degradation a palatable alternative for viruses. A further consideration is that facilitating the ubiquitin-independent degradation of their own protein products may allow viruses to evade adaptive immune

responses by keeping protein steady-state concentrations low, especially if the peptides produced by this mode of proteasomal degradation were less well incorporated into MHC molecules for extracellular presentation, thus disguising the infected cell from immune recognition. There is precedence for this type of viral strategy to avoid immune detection, as sequences in the EBV protein EBNA1 impair its proteasomal degradation and thus its presentation by MHC molecules [160].

A final question is whether or not proteasome-dependent, ubiquitin-independent degradation is a suitable target for anti-cancer and/or anti-viral therapeutics. Proteasomal degradation itself is clearly a valid target, as the proteasome inhibitor bortezomib is used clinically for the treatment of mantle cell lymphoma and multiple myeloma [33]. Therefore, one might suspect that specifically inhibiting the ubiquitin-independent proteasomal degradation events that appear to preferentially target cellular tumor suppressors and viral oncogenes could approach the therapeutic effect of complete proteasome inhibition without invoking as many deleterious side effects. As many viruses are inhibited *in vitro* by proteasome inhibitors [161–165], curtailing ubiquitin-independent degradation events certainly has therapeutic potential for viral infections. Because PA28 γ plays a conspicuous role in many ubiquitin-independent degradation events, modalities that inhibit its expression, function, or prevent it from associating with the 20S CP could provide therapeutically relevant inhibition.

In summary, the documentation and acceptance of proteasome-dependent, ubiquitin-independent degradation events are ever increasing. This relatively uncommon method of protein destruction is inextricably tied to viral infections and cancers. The description of more detailed mechanisms for a larger number of these events will advance their more general recognition and appreciation, as well as unveil targets for interventions to potentially treat infectious and proliferative diseases.

Acknowledgments

We thank Leanne Olds for the figure illustrations. This work was supported by NIH grant AI074984 to R.F.K. R.F.K. is a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease. L. W. is supported by NIH predoctoral training grant T32 CA009135.

References

- [1]. Chondrogianni N, Gonos ES. Proteasome function determines cellular homeostasis and the rate of aging. *Adv Exp Med Biol.* 2010; 694:38–46. [PubMed: 20886755]
- [2]. Klionsky DJ, Emr SD. Autophagy as a Regulated Pathway of Cellular Degradation. *Science.* 2000; 290:1717–1721. [PubMed: 11099404]
- [3]. Levine B, Kroemer G. Autophagy in the Pathogenesis of Disease. *Cell.* 2008; 132:27–42. [PubMed: 18191218]
- [4]. Lecker SH, Goldberg AL, Mitch WE. Protein Degradation by the Ubiquitin–Proteasome Pathway in Normal and Disease States. *Journal of the American Society of Nephrology.* 2006; 17:1807–1819. [PubMed: 16738015]
- [5]. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. *Cell.* 1994; 78:761–771. [PubMed: 8087844]
- [6]. Jung T, Catalgol B, Grune T. The proteasomal system. *Molecular Aspects of Medicine.* 2009; 30:191–296. [PubMed: 19371762]
- [7]. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. *Nat Rev Cancer.* 2006; 6:369–381. [PubMed: 16633365]
- [8]. Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. *Nat Rev Mol Cell Biol.* 2003; 4:192–201. [PubMed: 12612638]

- [9]. Krogan NJ, Lam MHY, Fillingham J, Keogh M-C, Gebbia M, Li J, Datta N, Cagney G, Buratowski S, Emili A, Greenblatt JF. Proteasome Involvement in the Repair of DNA Double-Strand Breaks. *Molecular Cell*. 2004; 16:1027–1034. [PubMed: 15610744]
- [10]. Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. *Cell Death Differ*. 1999; 6:303–313. [PubMed: 10381632]
- [11]. Adams J. The proteasome: a suitable antineoplastic target. *Nat Rev Cancer*. 2004; 4:349–360. [PubMed: 15122206]
- [12]. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. *Clin Cancer Res*. 2003; 9:6316–6325. [PubMed: 14695130]
- [13]. Blanchette P, Branton PE. Manipulation of the ubiquitin-proteasome pathway by small DNA tumor viruses. *Virology*. 2009; 384:317–323. [PubMed: 19013629]
- [14]. Petroski M. The ubiquitin system, disease, and drug discovery. *BMC Biochemistry*. 2008; 9:S7. [PubMed: 19007437]
- [15]. Loureiro, J.; Ploegh, HL. Antigen Presentation and the Ubiquitin-Proteasome System in Host-Pathogen Interactions. In: Frederick, WA., editor. *Advances in Immunology*. Vol. Volume 92. Academic Press; 2006. p. 225-305.
- [16]. Glickman MH, Ciechanover A. The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction. *Physiological Reviews*. 2002; 82:373–428. [PubMed: 11917093]
- [17]. Jariel-Encontre I, Bossis G, Piechaczyk M. Ubiquitin-independent degradation of proteins by the proteasome. *Biochim Biophys Acta*. 2008; 1786:153–177. [PubMed: 18558098]
- [18]. Kim HM, Yu Y, Cheng Y. Structure characterization of the 26S proteasome. *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*. In Press, Corrected Proof.
- [19]. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of 20S proteasome from yeast at 2.4 Å resolution. *Nature*. 1997; 386:463–471. [PubMed: 9087403]
- [20]. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, Finley D. A gated channel into the proteasome core particle. *Nat Struct Mol Biol*. 2000; 7:1062–1067.
- [21]. Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, Tsukihara T. The Structure of the Mammalian 20S Proteasome at 2.75 Å Resolution. *Structure (London, England : 1993)*. 2002; 10:609–618.
- [22]. Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. *Trends in Cell Biology*. 2005; 15:27–33. [PubMed: 15653075]
- [23]. Bedford L, Paine S, Sheppard PW, Mayer RJ, Roelofs J. Assembly, structure, and function of the 26S proteasome. *Trends Cell Biol*. 2010; 20:391–401. [PubMed: 20427185]
- [24]. Kuehn L, Dahlmann B. Structural and functional properties of proteasome activator PA28. *Molecular Biology Reports*. 1997; 24:89–93. [PubMed: 9228287]
- [25]. Sadre-Bazzaz K, Whitby FG, Robinson H, Formosa T, Hill CP. Structure of a Blm10 Complex Reveals Common Mechanisms for Proteasome Binding and Gate Opening. *Molecular Cell*. 2010; 37:728–735. [PubMed: 20227375]
- [26]. Blickwedehl J, Agarwal M, Seong C, Pandita RK, Melendy T, Sung P, Pandita TK, Bangia N. Role for proteasome activator PA200 and postglutamyl proteasome activity in genomic stability. *Proceedings of the National Academy of Sciences*. 2008; 105:16165–16170.
- [27]. Xu P, Duong DM, Seyfried NT, Cheng D, Xie Y, Robert J, Rush J, Hochstrasser M, Finley D, Peng J. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. *Cell*. 2009; 137:133–145. [PubMed: 19345192]
- [28]. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A Novel Ubiquitination Factor, E4, Is Involved in Multiubiquitin Chain Assembly. *Cell*. 1999; 96:635–644. [PubMed: 10089879]
- [29]. Husnjak K, Elsasser S, Zhang N, Chen X, Randles L, Shi Y, Hofmann K, Walters KJ, Finley D, Dikic I. Proteasome subunit Rpn13 is a novel ubiquitin receptor. *Nature*. 2008; 453:481–488. [PubMed: 18497817]
- [30]. Elsasser S, Chandler-Militello D, Müller B, Hanna J, Finley D. Rad23 and Rpn10 Serve as Alternative Ubiquitin Receptors for the Proteasome. *Journal of Biological Chemistry*. 2004; 279:26817–26822. [PubMed: 15117949]

- [31]. Finley D. Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome. *Annual Review of Biochemistry*. 2009; 78:477–513.
- [32]. Peth A, Uchiki T, Goldberg AL. ATP-dependent steps in the binding of ubiquitin conjugates to the 26S proteasome that commit to degradation. *Mol Cell*. 2010; 40:671–681. [PubMed: 21095592]
- [33]. Ruggeri, B.; Miknyoczki, S.; Dorsey, B.; Hui, A-M. The Development and Pharmacology of Proteasome Inhibitors for the Management and Treatment of Cancer. In: Enna, S.J.; Michael, W., editors. *Advances in Pharmacology*. Vol. Volume 57. Academic Press; 2009. p. 91-135.
- [34]. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. *Biochem Biophys Res Commun*. 1995; 217:1070–1077. [PubMed: 8554559]
- [35]. Fujita E, Mukasa T, Tsukahara T, Arahata K, Omura S, Momoi T. Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors. *Biochem Biophys Res Commun*. 1996; 224:74–79. [PubMed: 8694836]
- [36]. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. *Nat Rev Cancer*. 2010; 10:550–560. [PubMed: 20592731]
- [37]. Harhaj EW, Harhaj NS. Mechanisms of persistent NF-kappaB activation by HTLV-I tax. *IUBMB Life*. 2005; 57:83–91. [PubMed: 16036567]
- [38]. Griffin BD, Verweij MC, Wiertz EJHJ. Herpesviruses and immunity: The art of evasion. *Veterinary Microbiology*. 2010; 143:89–100. [PubMed: 20303681]
- [39]. Antoniou AN, Powis SJ. Pathogen evasion strategies for the major histocompatibility complex class I assembly pathway. *Immunology*. 2008; 124:1–12. [PubMed: 18284468]
- [40]. Sdek P, Ying H, Chang DLF, Qiu W, Zheng H, Touitou R, Allday MJ, Xiao Z.-X. Jim. MDM2 Promotes Proteasome-Dependent Ubiquitin-Independent Degradation of Retinoblastoma Protein. *Molecular Cell*. 2005; 20:699–708. [PubMed: 16337594]
- [41]. Jin Y, Lee H, Zeng SX, Dai M-S, Lu H. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. *Embo J*. 2003; 22:6365–6377. [PubMed: 14633995]
- [42]. Murakami Y, Matsufuji S, Kameji T, Hayashi S.-i. Igarashi K, Tamura T, Tanaka K, Ichihara A. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. *Nature*. 1992; 360:597–599. [PubMed: 1334232]
- [43]. Zhang M, Pickart CM, Coffino P. Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate. *Embo J*. 2003; 22:1488–1496. [PubMed: 12660156]
- [44]. Takeuchi J, Chen H, Hoyt MA, Coffino P. Structural elements of the ubiquitin-independent proteasome degraon of ornithine decarboxylase. *Biochem J*. 2008; 410:401–407. [PubMed: 17979831]
- [45]. Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, Qin J, Tsai SY, Tsai MJ, O'Malley BW. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. *Cell*. 2006; 124:381–392. [PubMed: 16439211]
- [46]. Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O'Malley BW. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. *Mol Cell*. 2007; 26:831–842. [PubMed: 17588518]
- [47]. Chen X, Barton LF, Chi Y, Clurman BE, Roberts JM. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. *Mol Cell*. 2007; 26:843–852. [PubMed: 17588519]
- [48]. Moriishi K, Okabayashi T, Nakai K, Moriya K, Koike K, Murata S, Chiba T, Tanaka K, Suzuki R, Suzuki T, Miyamura T, Matsuura Y. Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. *J Virol*. 2003; 77:10237–10249. [PubMed: 12970408]
- [49]. Stadtmueller BM, Hill CP. Proteasome activators. *Mol Cell*. 2011; 41:8–19. [PubMed: 21211719]
- [50]. Shay JW, Wright WE, Werbin H. Defining the molecular mechanisms of human cell immortalization. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*. 1991; 1072:1–7.

- [51]. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. *Nat Rev Cancer*. 2010; 10:878–889. [PubMed: 21102637]
- [52]. zur Hausen H. Papillomaviruses in the causation of human cancers -- a brief historical account. *Virology*. 2009; 384:260–265. [PubMed: 19135222]
- [53]. Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. *Neoplasia*. 2009; 11:1–9. [PubMed: 19107226]
- [54]. Cinatl J Jr, Vogel JU, Kotchetkov R, Doerr H, Wilhelm. Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. *FEMS Microbiol Rev*. 2004; 28:59–77. [PubMed: 14975530]
- [55]. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. *J Natl Cancer Inst*. 2000; 92:690–698. [PubMed: 10793105]
- [56]. Boyer SN, Wazer DE, Band V. E7 Protein of Human Papilloma Virus-16 Induces Degradation of Retinoblastoma Protein through the Ubiquitin-Proteasome Pathway. *Cancer Research*. 1996; 56:4620–4624. [PubMed: 8840974]
- [57]. Felsani A, Mileo AM, Paggi MG. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. *Oncogene*. 2006; 25:5277–5285. [PubMed: 16936748]
- [58]. Morris JD, Crook T, Bandara LR, Davies R, LaThangue NB, Vousden KH. Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. *Oncogene*. 1993; 8:893–898. [PubMed: 8455943]
- [59]. Huh K, Zhou X, Hayakawa H, Cho J-Y, Libermann TA, Jin J, Harper J, Wade, Munger K. Human Papillomavirus Type 16 E7 Oncoprotein Associates with the Cullin 2 Ubiquitin Ligase Complex, Which Contributes to Degradation of the Retinoblastoma Tumor Suppressor. *J. Virol*. 2007; 81:9737–9747. [PubMed: 17609271]
- [60]. Scheffner M, Werness B, Huibregtse J, Levine A, Howley P. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. *Cell*. 1990; 63:1129–1136. [PubMed: 2175676]
- [61]. Vousden KH, Lu X. Live or let die: the cell's response to p53. *Nat Rev Cancer*. 2002; 2:594–604. [PubMed: 12154352]
- [62]. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. *Nature*. 1991; 351:453–456. [PubMed: 2046748]
- [63]. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. *Science*. 1991; 253:49–53. [PubMed: 1905840]
- [64]. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. *Nat Rev Cancer*. 2009; 9:862–873. [PubMed: 19935675]
- [65]. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. *Nature*. 1997; 387:296–299. [PubMed: 9153395]
- [66]. Scheffner M, Huibregtse J, Vierstra R, Howley P. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. *Cell*. 1993; 75:495–505. [PubMed: 8221889]
- [67]. Camus S, Menendez S, Cheok CF, Stevenson LF, Lain S, Lane DP. Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. *Oncogene*. 2007; 26:4059–4070. [PubMed: 17224909]
- [68]. Li X, Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. *J Virol*. 1996; 70:4509–4516. [PubMed: 8676476]
- [69]. Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. *Pharmacology & Therapeutics*. 2003; 98:269–297. [PubMed: 12782241]
- [70]. Mocarski, ES.; Shenk, T.; Pass, RF. Cytomegaloviruses. In: Knipe, DM.; Howley, PM., editors. *Fields Virology*. Lippincott; Philadelphia: 2007. p. 2701-2772.
- [71]. Harkins LE, Matlaf LA, Soroceanu L, Klemm K, Britt WJ, Wang W, Bland KI, Cobbs CS. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. *Herpesviridae*. 2010; 1:8. [PubMed: 21429243]
- [72]. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144:646–674. [PubMed: 21376230]

- [73]. Slinger E, Langemeijer E, Siderius M, Vischer HF, Smit MJ. Herpesvirus-encoded GPCRs rewire cellular signaling. *Molecular and Cellular Endocrinology*. 2011; 331:179–184. [PubMed: 20398729]
- [74]. Yurochko AD. Human cytomegalovirus modulation of signal transduction. *Curr Top Microbiol Immunol*. 2008; 325:205–220. [PubMed: 18637508]
- [75]. Sanchez V, Spector DH. Subversion of cell cycle regulatory pathways. *Curr Top Microbiol Immunol*. 2008; 325:243–262. [PubMed: 18637510]
- [76]. Hume AJ, Kalejta RF. Regulation of the retinoblastoma proteins by the human herpesviruses. *Cell Div*. 2009; 4:1. [PubMed: 19146698]
- [77]. Loewendorf A, Benedict CA. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. *Journal of Internal Medicine*. 2010; 267:483–501. [PubMed: 20433576]
- [78]. Crough T, Khanna R. Immunobiology of Human Cytomegalovirus: from Bench to Bedside. *Clin. Microbiol. Rev*. 2009; 22:76–98. [PubMed: 19136435]
- [79]. Strååt K, Liu C, Rahbar A, Zhu Q, Liu L, Wolmer-Solberg N, Lou F, Liu Z, Shen J, Jia J, Kyo S, Björkholm M, Sjöberg J, Söderberg-Nauclér C, Xu D. Activation of Telomerase by Human Cytomegalovirus. *Journal of the National Cancer Institute*. 2009; 101:488–497. [PubMed: 19318640]
- [80]. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. *Curr Top Microbiol Immunol*. 2008; 325:417–470. [PubMed: 18637519]
- [81]. Vomaske J, Varnum S, Melnychuk R, Smith P, Pasa-Tolic L, Shutthanandan II, Streblow DN. HCMV pUS28 initiates pro-migratory signaling via activation of Pyk2 kinase. *Herpesviridae*. 2010; 1:2. [PubMed: 21429240]
- [82]. Chan G, Nogalski MT, Yurochko AD. Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. *Proc Natl Acad Sci U S A*. 2009; 106:22369–22374. [PubMed: 20018733]
- [83]. Caposio P, Orloff SL, Streblow DN. The role of cytomegalovirus in angiogenesis. *Virus Res*. 2010
- [84]. Fortunato EA, Dell'Aquila ML, Spector DH. Specific chromosome 1 breaks induced by human cytomegalovirus. *Proc Natl Acad Sci U S A*. 2000; 97:853–858. [PubMed: 10639169]
- [85]. Shen Y, Zhu H, Shenk T. Human cytomegalovirus IE1 and IE2 proteins are mutagenic and mediate “hit-and-run” oncogenic transformation in cooperation with the adenovirus E1A proteins. *Proceedings of the National Academy of Sciences*. 1997; 94:3341–3345.
- [86]. Siew VK, Duh CY, Wang SK. Human cytomegalovirus UL76 induces chromosome aberrations. *J Biomed Sci*. 2009; 16:107. [PubMed: 19930723]
- [87]. Brune W. Inhibition of programmed cell death by cytomegaloviruses. *Virus Res*. 2010; 157:144–150. [PubMed: 20969904]
- [88]. Spencer CM, Schafer XL, Moorman NJ, Munger J. Human Cytomegalovirus Induces the Activity and Expression of Acetyl-CoA Carboxylase, a Fatty Acid Biosynthetic Enzyme whose Inhibition Attenuates Viral Replication. *J. Virol*. 2011 JVI.02630-02610.
- [89]. Chambers JW, Maguire TG, Alwine JC. Glutamine Metabolism Is Essential for Human Cytomegalovirus Infection. *J. Virol*. 2010; 84:1867–1873. [PubMed: 19939921]
- [90]. Kalejta RF. Tegument proteins of human cytomegalovirus. *Microbiol Mol Biol Rev*. 2008; 72:249–265. [PubMed: 18535146]
- [91]. Hofmann H, Sindre H, Stamminger T. Functional Interaction between the pp71 Protein of Human Cytomegalovirus and the PML-Interacting Protein Human Daxx. *J. Virol*. 2002; 76:5769–5783. [PubMed: 11992005]
- [92]. Cantrell SR, Bresnahan WA. Interaction between the human cytomegalovirus UL82 gene product (pp71) and hDaxx regulates immediate-early gene expression and viral replication. *J Virol*. 2005; 79:7792–7802. [PubMed: 15919932]
- [93]. Lee, S.; Kalejta, RF.; Kerry, JA.; Semmes, OJ.; O'Connor, C.; Kahn, Z.; Garcia, B.; Shenk, T.; Murphy, E. BclAF1 restriction factor neutralized by proteasomal degradation and microRNA repression during human cytomegalovirus infection. (Unpublished Results)

- [94]. Kalejta RF, Bechtel JT, Shenk T. Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasome-dependent degradation of the retinoblastoma family of tumor suppressors. *Mol Cell Biol.* 2003; 23:1885–1895. [PubMed: 12612064]
- [95]. Saffert RT, Kalejta RF. Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression. *J Virol.* 2006; 80:3863–3871. [PubMed: 16571803]
- [96]. Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, Kalejta RF. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. *Science.* 2008; 320:797–799. [PubMed: 18467589]
- [97]. Kalejta RF, Shenk T. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. *Proc Natl Acad Sci U S A.* 2003; 100:3263–3268. [PubMed: 12626766]
- [98]. Hwang J, Kalejta RF. Proteasome-dependent, ubiquitin-independent degradation of Daxx by the viral pp71 protein in human cytomegalovirus-infected cells. *Virology.* 2007; 367:334–338. [PubMed: 17590404]
- [99]. Bhattacharya S, Garriga J, Calbo J, Yong T, Haines DS, Grana X. SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. *Oncogene.* 2003; 22:2443–2451. [PubMed: 12717421]
- [100]. Herrmann J, Lerman LO, Lerman A. Ubiquitin and Ubiquitin-Like Proteins in Protein Regulation. *Circ Res.* 2007; 100:1276–1291. [PubMed: 17495234]
- [101]. Hwang J, Kalejta RF. Human cytomegalovirus protein pp71 induces Daxx SUMOylation. *J Virol.* 2009; 83:6591–6598. [PubMed: 19369322]
- [102]. Kahana C, Asher G, Shaul Y. Mechanisms of protein degradation: an odyssey with ODC. *Cell Cycle.* 2005; 4:1461–1464. [PubMed: 16205122]
- [103]. Fehr AR, Yu D. Human Cytomegalovirus Gene UL21a Encodes a Short-Lived Cytoplasmic Protein and Facilitates Virus Replication in Fibroblasts. *J. Virol.* 2010; 84:291–302. [PubMed: 19846516]
- [104]. Peña MMO, Melo SP, Xing Y-Y, White K, Barbour KW, Berger FG. The Intrinsically Disordered N-terminal Domain of Thymidylate Synthase Targets the Enzyme to the Ubiquitin-independent Proteasomal Degradation Pathway. *Journal of Biological Chemistry.* 2009; 284:31597–31607. [PubMed: 19797058]
- [105]. Bolin LL, Hanson LK, Slater JS, Kerry JA, Campbell AE. Murine Cytomegalovirus US22 Protein pM140 Protects Its Binding Partner, pM141, from Proteasome-Dependent but Ubiquitin-Independent Degradation. *J. Virol.* 2010; 84:2164–2168. [PubMed: 19955315]
- [106]. Ranger-Zisman B, Palmon A, Blagerman S, Tel-Or S, Benharroch D, Pecht M, Trainin N, Burstein Y. Novel therapeutic strategies against cytomegalovirus infection. *Nat Immun.* 1995; 14:250–261. [PubMed: 8933819]
- [107]. Hanson LK, Slater JS, Karabekian Z, Ciocco-Schmitt G, Campbell AE. Products of US22 genes M140 and M141 confer efficient replication of murine cytomegalovirus in macrophages and spleen. *J Virol.* 2001; 75:6292–6302. [PubMed: 11413295]
- [108]. Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. *Trends Biochem Sci.* 1996; 21:267–271. [PubMed: 8755249]
- [109]. Siegl G. Molecular biology and pathogenicity of human and animal parvoviruses. *Behring Inst Mitt.* 1990:6–13. [PubMed: 2171487]
- [110]. Ayuso E, Mingozzi F, Bosch F. Production, purification and characterization of adeno-associated vectors. *Curr Gene Ther.* 2010; 10:423–436. [PubMed: 21054248]
- [111]. Miller CL, Pintel DJ. The NS2 protein generated by the parvovirus minute virus of mice is degraded by the proteasome in a manner independent of ubiquitin chain elongation or activation. *Virology.* 2001; 285:346–355. [PubMed: 11437668]
- [112]. Naeger LK, Cater J, Pintel DJ. The small nonstructural protein (NS2) of the parvovirus minute virus of mice is required for efficient DNA replication and infectious virus production in a cell-type-specific manner. *J Virol.* 1990; 64:6166–6175. [PubMed: 2147041]

- [113]. Cotmore SF, D'Abramo AM Jr, Carbonell LF, Bratton J, Tattersall P. The NS2 polypeptide of parvovirus MVM is required for capsid assembly in murine cells. *Virology*. 1997; 231:267–280. [PubMed: 9168889]
- [114]. De Mitri MS, Cassini R, Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. *Eur J Cancer*. 2010; 46:2178–2186. [PubMed: 20413301]
- [115]. Yen TS. Hepadnaviral X Protein: Review of Recent Progress. *J Biomed Sci*. 1996; 3:20–30. [PubMed: 11725079]
- [116]. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. *J Virol*. 2004; 78:12725–12734. [PubMed: 15542625]
- [117]. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. *Nature*. 1991; 351:317–320. [PubMed: 2034275]
- [118]. Hu Z, Zhang Z, Doo E, Coux O, Goldberg AL, Liang TJ. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. *J Virol*. 1999; 73:7231–7240. [PubMed: 10438810]
- [119]. Kim JH, Sohn SY, Yen T.S, Benedict, Ahn BY. Ubiquitin-dependent and -independent proteasomal degradation of hepatitis B virus X protein. *Biochem Biophys Res Commun*. 2008; 366:1036–1042. [PubMed: 18155658]
- [120]. Stohwasser R, Holzthutter HG, Lehmann U, Henklein P, Kloetzel PM. Hepatitis B virus HBx peptide 116-138 and proteasome activator PA28 compete for binding to the proteasome alpha4/MC6 subunit. *Biol Chem*. 2003; 384:39–49. [PubMed: 12674498]
- [121]. Zhang Z, Torii N, Furusaka A, Malayaman N, Hu Z, Liang TJ. Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex. *J Biol Chem*. 2000; 275:15157–15165. [PubMed: 10748218]
- [122]. Barak O, Aronheim A, Shaul Y. HBV X protein targets HIV Tat-binding protein 1. *Virology*. 2001; 283:110–120. [PubMed: 11312667]
- [123]. Cheetham ME, Caplan AJ. Structure, function and evolution of DnaJ: conservation and adaptation of chaperone function. *Cell Stress Chaperones*. 1998; 3:28–36. [PubMed: 9585179]
- [124]. Braun BC, Glickman M, Kraft R, Dahlmann B, Kloetzel PM, Finley D, Schmidt M. The base of the proteasome regulatory particle exhibits chaperone-like activity. *Nat Cell Biol*. 1999; 1:221–226. [PubMed: 10559920]
- [125]. Sohn SY, Kim JH, Baek KW, Ryu WS, Ahn BY. Turnover of hepatitis B virus X protein is facilitated by Hdj1, a human Hsp40/DnaJ protein. *Biochem Biophys Res Commun*. 2006; 347:764–768. [PubMed: 16842747]
- [126]. Lee DH, Sherman MY, Goldberg AL. Involvement of the molecular chaperone Ydj1 in the ubiquitin-dependent degradation of short-lived and abnormal proteins in *Saccharomyces cerevisiae*. *Mol Cell Biol*. 1996; 16:4773–4781. [PubMed: 8756635]
- [127]. Gallo RC. Human retroviruses after 20 years: a perspective from the past and prospects for their future control. *Immunol Rev*. 2002; 185:236–265. [PubMed: 12190935]
- [128]. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. *Annu Rev Med*. 2011; 62:141–155. [PubMed: 21090961]
- [129]. da Silva, S. Ramos; de Oliveira, D. Elgui HIV, EBV and KSHV: Viral cooperation in the pathogenesis of human malignancies. *Cancer Lett*. 2011
- [130]. Zhou M, Halanski MA, Radonovich MF, Kashanchi F, Peng J, Price DH, Brady JN. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. *Mol Cell Biol*. 2000; 20:5077–5086. [PubMed: 10866664]
- [131]. Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. *Expert Opin Pharmacother*. 2011; 12:31–46. [PubMed: 20698725]
- [132]. Bres V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Treand C, Emiliani S, Peloponese JM, Jeang KT, Coux O, Scheffner M, Benkirane M. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. *Nat Cell Biol*. 2003; 5:754–761. [PubMed: 12883554]

- [133]. Gargano B, Fiorillo M, Amente S, Majello B, Lania L. p14ARF is capable of promoting HIV-1 tat degradation. *Cell Cycle*. 2008; 7:1433–1439. [PubMed: 18418067]
- [134]. Mao I, Liu J, Li X, Luo H. REGgamma, a proteasome activator and beyond? *Cell Mol Life Sci*. 2008; 65:3971–3980. [PubMed: 18679578]
- [135]. Apcher GS, Heink S, Zantopf D, Kloetzel PM, Schmid HP, Mayer RJ, Kruger E. Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal alpha and beta subunits. *FEBS Lett*. 2003; 553:200–204. [PubMed: 14550573]
- [136]. Nelbock P, Dillon P, Perkins A, Rosen C. A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator. *Science*. 1990; 248:1650–1653. [PubMed: 2194290]
- [137]. Matsuoka M, Jeang K-T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. *Nat Rev Cancer*. 2007; 7:270–280. [PubMed: 17384582]
- [138]. Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. *Oncogene*. 2011; 30:1379–1389. [PubMed: 21119600]
- [139]. Nyborg JK, Egan D, Sharma N. The HTLV-1 Tax protein: Revealing mechanisms of transcriptional activation through histone acetylation and nucleosome disassembly. *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*. 1799:266–274.
- [140]. Rosin O, Koch C, Schmitt I, Semmes OJ, Jeang K-T, Grassmann R. A Human T-cell Leukemia Virus Tax Variant Incapable of Activating NF- κ B Retains Its Immortalizing Potential for Primary T-lymphocytes. *Journal of Biological Chemistry*. 1998; 273:6698–6703. [PubMed: 9506967]
- [141]. Robek MD, Ratner L. Immortalization of CD4+ and CD8+ T Lymphocytes by Human T-Cell Leukemia Virus Type 1 Tax Mutants Expressed in a Functional Molecular Clone. *J. Virol*. 1999; 73:4856–4865. [PubMed: 10233947]
- [142]. Pozzatti R, Vogel J, Jay G. The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells. *Mol. Cell. Biol*. 1990; 10:413–417. [PubMed: 2403646]
- [143]. Sun SC, Ballard DW. Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: hijacking cellular IkappaB kinases. *Oncogene*. 1999; 18:6948–6958. [PubMed: 10602469]
- [144]. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. *Oncogene*. 1999; 18:6853–6866. [PubMed: 10602461]
- [145]. Pomerantz JL, Baltimore D. Two Pathways to NF-[kappa]B. *Molecular Cell*. 2002; 10:693–695. [PubMed: 12419209]
- [146]. Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, Ballard DW. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. *Mol Cell Biol*. 1995; 15:2809–2818. [PubMed: 7739562]
- [147]. Scherer DC, Brockman JA, Chen Z, Maniatis T, Ballard DW. Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. *Proc Natl Acad Sci U S A*. 1995; 92:11259–11263. [PubMed: 7479976]
- [148]. Petropoulos L, Hiscott J. Association between HTLV-1 Tax and I kappa B alpha is dependent on the I kappa B alpha phosphorylation state. *Virology*. 1998; 252:189–199. [PubMed: 9875328]
- [149]. Rousset R, Desbois C, Bantignies F, Jalinot P. Effects on NF-kappa B1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome. *Nature*. 1996; 381:328–331. [PubMed: 8692272]
- [150]. Kehn K, Fuente de LC, Strouss K, Berro R, Jiang H, Brady J, Mahieux R, Pumfery A, Bottazzi ME, Kashanchi F. The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. *Oncogene*. 2005; 24:525–540. [PubMed: 15580311]
- [151]. Rollinger JM, Schmidtke M. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. *Med Res Rev*. 2011; 31:42–92. [PubMed: 19714577]
- [152]. Ehrenfeld E, Modlin J, Chumakov K. Future of polio vaccines. *Expert Rev Vaccines*. 2009; 8:899–905. [PubMed: 19545205]

- [153]. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. *Nat Rev Microbiol.* 2007; 5:453–463. [PubMed: 17487147]
- [154]. Giannini C, Brechot C. Hepatitis C virus biology. *Cell Death Differ.* 2003; 10(Suppl 1):S27–38. [PubMed: 12655344]
- [155]. Shirakura M, Murakami K, Ichimura T, Suzuki R, Shimoji T, Fukuda K, Abe K, Sato S, Fukasawa M, Yamakawa Y, Nishijima M, Moriishi K, Matsuura Y, Wakita T, Suzuki T, Howley PM, Miyamura T, Shoji I. E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. *J Virol.* 2007; 81:1174–1185. [PubMed: 17108031]
- [156]. Suzuki R, Moriishi K, Fukuda K, Shirakura M, Ishii K, Shoji I, Wakita T, Miyamura T, Matsuura Y, Suzuki T. Proteasomal turnover of hepatitis C virus core protein is regulated by two distinct mechanisms: a ubiquitin-dependent mechanism and a ubiquitin-independent but PA28gamma-dependent mechanism. *J Virol.* 2009; 83:2389–2392. [PubMed: 19091860]
- [157]. Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, Murata S, Tanaka K, Miyamura T, Suzuki T, Koike K, Matsuura Y. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. *Proc Natl Acad Sci U S A.* 2007; 104:1661–1666. [PubMed: 17234812]
- [158]. Yuksek K, Chen WL, Chien D, Ou JH. Ubiquitin-independent degradation of hepatitis C virus F protein. *J Virol.* 2009; 83:612–621. [PubMed: 18971267]
- [159]. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, Finley D. A gated channel into the proteasome core particle. *Nat Struct Biol.* 2000; 7:1062–1067. [PubMed: 11062564]
- [160]. Dantuma NP, Sharipo A, Masucci MG. Avoiding proteasomal processing: the case of EBNA1. *Curr Top Microbiol Immunol.* 2002; 269:23–36. [PubMed: 12224511]
- [161]. La Frazia S, Amici C, Santoro MG. Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB. *Antivir Ther.* 2006; 11:995–1004. [PubMed: 17302369]
- [162]. Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princiotta MF, Bannink JR, Krausslich HG, Yewdell JW. Proteasome inhibition interferes with gag polypeptide processing, release, and maturation of HIV-1 and HIV-2. *Proc Natl Acad Sci U S A.* 2000; 97:13057–13062. [PubMed: 11087859]
- [163]. Prosch S, Priemer C, Hoflich C, Liebentha C, Babel N, Kruger DH, Volk HD. Proteasome inhibitors: a novel tool to suppress human cytomegalovirus replication and virus-induced immune modulation. *Antivir Ther.* 2003; 8:555–567. [PubMed: 14760889]
- [164]. Harty RN, Brown ME, McGettigan JP, Wang G, Jayakar HR, Huibregtse JM, Whitt MA, Schnell MJ. Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. *J Virol.* 2001; 75:10623–10629. [PubMed: 11602704]
- [165]. Watanabe H, Tanaka Y, Shimazu Y, Sugahara F, Kuwayama M, Hiramatsu A, Kiyotani K, Yoshida T, Sakaguchi T. Cell-specific inhibition of paramyxovirus maturation by proteasome inhibitors. *Microbiol Immunol.* 2005; 49:835–844. [PubMed: 16172538]

Figure 1. Models for ubiquitin-independent proteasomal degradation

A. Substrates undergoing proteasome-dependent, ubiquitin-independent degradation often associate with the 20S CP. This association can be direct and autonomous (i), direct but mediated by an accessory protein (ii), or indirect and mediated by an accessory protein (iii).

B. Other proteasome-dependent ubiquitin-independent degradation substrates associate with proteasome activators. Mechanisms include substrate association with the 19S RP either independently (iv), with an accessory protein (v), or after conjugation with a ubiquitin-like protein (vi), as well as direct association with PA28γ (vii). Design adapted from reference 17.

Figure 2. Ubiquitin-independent proteasomal degradation events *in vivo*

The 20S CP alone or in association with various activators (19S RP, PA28αβ, PA200, PA28γ) mediates protein degradation (see text for details). Documented examples of ubiquitin-independent degradation events in uninfected cells (grey boxes) or in virus protein-expressing cells (yellow boxes) are displayed adjacent to the proteasomal components that mediate the event. Other proteasome-dependent, ubiquitin-independent degradation events in viral protein-expressing cells have not been ascribed to a specific proteasomal assemblage (white box). Design adapted from reference 17.

Table 1

Ubiquitin-independent degradation assays

Assay	Strengths	Weaknesses
Absence of ubiquitination	Can be a visually compelling, companion experiment.	Ubiquitinated intermediates are short-lived and challenging to isolate, so negative results are difficult to interpret without extensive positive controls.
Unstable in ^a ts20 cells	Most direct and reliable assay when proper ubiquitin-dependent controls are also analyzed.	Positive controls such as p53 only show ubiquitin-dependent degradation impairment but not necessarily a complete inhibition; Possibility that specific degradation events depend more highly on Ube 1L2 as opposed to the ts Ube 1 protein.
Immune to ^b DN ubiquitin	Direct and reliable assay when proper ubiquitin-dependent controls are also analyzed.	Transfection based assay in which it is difficult to achieve high-level inhibition even of positive controls.
Unstable lysine-less mutant	Simple assay for a subset of small proteins but that requires inhibitors to confirm proteasome-mediated degradation.	Larger proteins require multiple lysine mutations that may affect overall structure; Must be conscious of N-terminal-mediated ubiquitin-dependent degradation.
<i>In vitro</i> degradation	Defined assay favored by protein biochemists.	Inability to confirm that processes that can occur <i>in vitro</i> actually do occur <i>In vitro</i> ; Technically demanding assay that requires all necessary reaction components (which may or may not be known).

^ats20: temperature sensitive^bDN: dominant negative

Table 2

Viruses and ubiquitin-independent protein degradation by proteasomes

Virus class	Degradation inducer	Target substrate	Absence of ubiquitination	Unstable in ts20 cells	Immune to cDN ubiquitin	Unstable lysine-less mutant	<i>In vitro</i> degradation	Compelling arguments for ubiquitin-independent degradation?	Proposed mechanisms	References
^a DS-DNA viruses	HPV E6	p53	✓	✓	✓			Yes	20S ^d CP recognition of p53 upon C-terminus binding to E6	67
	HCMV pp71	Daxx		✓				Yes	pp71-induced substrate binding to 19S ^e RP	98, Winkler and Kalejta (manuscript in prep)
	HCMV pp71	Rb, p107, p130	✓	✓	✓			Yes	pp71-induced substrate binding to 19S RP	97, Winkler and Kalejta (manuscript in prep)
	?	HCMV pUL21a	✓	✓			✓	Yes	20S CP recognition of unstructured pUL21a C-terminal domain	103
^b SS-DNA viruses	?	MCMV M141	✓	✓				Yes	C-terminal/PEST domain as degradation signal	105
	?	MVM NS2	✓	✓	✓			Yes	20S CP recognition of NS2 C-terminus	111
	?	HBV X		✓				Not yet	20S CP binding; Chaperone Hdj1 participation	119-123
Reverse transcribing viruses	p14 ^{ARF}	HIV Tat					✓	Not yet	20S CP binding; PA28 ^γ participation	133, 135-136
	HTLV Tax	IκBα					✓	Not yet	Tax-mediated recruitment of IκBα to 20S CP	148-149
Positive strand RNA viruses	?	HCV core					✓	Yes	20S CP binding; PA28 ^γ participation	156
	?	HCV F		✓			✓	Yes	20S CP recognition of F (aa 20-60)	158

^a DS-DNA: double stranded DNA

^b SS-DNA: single stranded DNA

c_{DN} : dominant-negative

d_{CP} : core particle

e_{RP} : regulatory particle

f_{PEST} : proline (P), glutamic acid (E), serine (S), and threonine (T).

Table 3**Hallmarks of Cancer Induced by HCMV**

Cancer Hallmark	HCMV function	Examples
Sustaining Proliferative Signaling	^a US28, viral infection	73-74
Evading Growth Suppressors	^b pp71, ^c UL97, ^d IE1, IE2, US28	75-76
Avoiding Immune Destruction	UL16, UL18, UL40, UL111a, UL141, UL142, UL144, US2, US3, US6, US8, US10, US11, IE2, pp71, pp65, ^e miR-UL112-1	77-78
Enabling Replicative Immortality	IE1, viral infection	79
Tumor Promoting Inflammation	US28, viral infection	73, 80
Activating Invasion and Metastasis	US28, viral infection	81-82
Inducing Angiogenesis	US28, IE1, viral secretome	83
Genome Instability and Mutation	IE1, IE2, UL76, viral infection	84-86
Resisting Cell Death	IE1, IE2, UL36, UL37x1, UL38, B2.7	87
Deregulating Cellular Energetics	viral infection	88-89

^aUS: unique short

^bpp: phospho protein

^cUL: unique long

^dIE: Immediate-early

^emiR: microRNA